TARS - NASDAQ
Tarsus Pharmaceuticals, Inc.
$58.76
-0.29%Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
At a Glance
Live Snapshottars
Total Liabilities
Last Annual Value
218.73M
3-Year CAGR
84%
5-Year CAGR
105%
10-Year CAGR
50%
Tarsus Pharmaceuticals, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Tarsus Pharmaceuticals, Inc. NASDAQ:TARS | 218.73M | 47.3% | 78.2% | N/A | |
 Celcuity Inc. NASDAQ:CELC | 366.00M | 92.3% | 84.3% | 95.6% | |
 Arcutis Biotherapeutics, Inc. NASDAQ:ARQT | 243.49M | -1.2% | 17.1% | N/A | |
 Legend Biotech Corporation NASDAQ:LEGN | 731.60M | 7.0% | 15.7% | N/A | |
 Adaptive Biotechnologies Corporation NASDAQ:ADPT | 287.74M | -6.6% | -2.1% | N/A | |
 CG Oncology, Inc. Common stock NASDAQ:CGON | 38.99M | 39.0% | 16.2% | N/A | |
 Disc Medicine, Inc. NASDAQ:IRON | 67.05M | 43.1% | -15.6% | N/A | |
 Scholar Rock Holding Corporation NASDAQ:SRRK | 158.78M | 22.8% | 3.7% | 9.7% | |
 Travere Therapeutics, Inc. NASDAQ:TVTX | 490.36M | -5.9% | 0.7% | 8.5% |
Tarsus Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your TARS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.